FDA Delays Decision on New Alzheimer’s Drug
FRIDAY, March 8, 2024 (HealthDay News) — Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely by an expert panel, the drug’s maker said Friday. “The FDA has informed LillyContinue Reading